GoodRx CEO addressed the company's underperformance on August 13, 2025, as Rite Aid bankruptcy caused stores to be removed from networks. Inquiries focused on pharma manufacturer solutions growth.
4 reports, 3 independent
Updated Sep 3
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 4
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
GoodRx CEO addressed the company's underperformance on August 13, 2025, as Rite Aid bankruptcy caused stores to be removed from networks. Inquiries focused on pharma manufacturer solutions growth.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Wendy Barnes leads GoodRx's strategy on healthcare access.1 source
- Rite Aid's Chapter 11 bankruptcy has led to widespread closures, with vacant locations being repurposed for new uses.Sub-event
- GoodRx reported that its revenue missed analyst estimates by 1.3% in August 2025.Sub-event
GoodRx CEO addressed underperformance amid Rite Aid bankruptcy and inquiries into pharma solutions growth.1 source
Keep exploring
The entities involved
Coverage
Newest first; wire copies grouped- aol.com
- StockStoryThe Top 5 Analyst Questions From GoodRx’s Q2 Earnings Call GoodRx’s second quarter results were met with a negative market reaction, as the company’s revenue fell short of Wall Street’s expectations
- StockStoryGDRX Q2 Deep Dive: Headwinds from Rite Aid and PBM Disruptions Offset Pharma Solutions Growth Healthcare tech company GoodRx (NASDAQ:GDRX) missed Wall Street’s revenue expectations in Q2 CY2025 as sa
- Business WireGoodRx Reports Second Quarter 2025 Results Second Quarter 2025 Revenue and Adjusted EBITDA Margin in Line with Previous Guidance; Pharma Manufacturer Solutions Revenue Increased 32% Year-Over-Year SA